Have any questions? 706-721-6582 or cts@augusta.edu
- (BCC015) Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Clinical Trial
(BCC015) Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
The purpose of this study is to evaluate an investigatinal drug called DFMO along with etoposide for Neuroblastoma. This study will look at the ability of this study drug to either keep your tumor in remission or if you have an active tumor, for your tumor to respond to the treatment and will also look at the safety and tolerability of DFMO.
Eligibility Criteria
- Children/young adults 21 or younger with a diagnosis of neuroblastoma. Subjects must have good cardiac (heart), liver and renal (kidney) function to participate. Subjects cannot be taking other investigational drugs.
RESEARCH. INNOVATION. DISCOVERY.